GlassScriptPhysician profile
Philip C Yee
NPI 1770666448
$5,813.66
in general payments reported to CMS, 2019-2025
28 companies · $1,972 in 2025
The $1,972 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $503 · 2020: $203 · 2021: $159 · 2022: $649 · 2023: $839 · 2024: $1,488 · 2025: $1,972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,247 · Education: $52.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,246.88 |
| Education | $52.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,170.01 | 2019-2025 | Linzess, Viberzi, Creon |
| Janssen Biotech, INC. | $1,118.91 | 2022-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $809.13 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $545.00 | 2019-2025 | Xifaxan, Trulance, Uceris |
| Vivus LLC | $279.78 | 2019-2025 | Pancreaze, Qsymia |
| Braintree Laboratories, INC. | $255.28 | 2019-2025 | Suflave, Sutab |
| Madrigal Pharmaceuticals | $241.80 | 2024-2025 | Rezdiffra, Resmetirom |
| Celltrion USA INC. | $229.63 | 2024-2025 | Vegzelma, Zymfentra |
| Gilead Sciences, INC. | $137.75 | 2022-2024 | |
| Fresenius Kabi USA, LLC | $120.56 | 2023-2024 | Idacio |
| Aimmune Therapeutics, INC. | $98.16 | 2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $97.93 | 2024 | Voquezna |
| Intercept Pharmaceuticals, INC. | $88.47 | 2022-2025 | Ocaliva |
| Medtronic USA, INC. | $81.87 | 2019 | |
| Nestle Healthcare Nutrition INC. | $66.53 | 2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $61.31 | 2019 | |
| Ardelyx, INC. | $57.56 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $56.06 | 2025 | Omvoh |
| Allergan, INC. | $45.35 | 2019 | |
| Celgene Corporation | $42.02 | 2023 | Zeposia |
| Merck Sharp & Dohme LLC | $40.39 | 2022 | |
| Ferring Pharmaceuticals INC. | $40.23 | 2022-2023 | Rebyota |
| Genzyme Corporation | $33.23 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $32.56 | 2025 | Iqirvo |
| Novo Nordisk INC | $22.42 | 2025 | Wegovy |
| Emergent Biosolutions INC. | $15.07 | 2019 | |
| Boston Scientific Corporation | $14.74 | 2019 | |
| Davol INC. | $11.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Yee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.